Can Wegovy cause eyesight problems?

What exactly is NAION, and why did it appear in the semaglutide headlines?

Non-arteritic anterior ischaemic optic neuropathy sounds dense, but the clinical picture is striking: sudden, painless loss of vision, usually in one eye, caused by interrupted blood flow to the optic nerve head. It is uncommon in the general population. In 2024 a retrospective study published in JAMA Ophthalmology compared patients taking semaglutide (both the Ozempic formulation for diabetes and the Wegovy formulation for weight management) against patients taking other diabetes or weight-loss medicines. Those on semaglutide had a statistically higher rate of NAION diagnoses.

The numbers are worth stating clearly. The study found roughly four additional NAION cases per ten thousand patients over a two-year follow-up, a relative increase that looks meaningful statistically, but an absolute risk that remains small. The research raised a genuine signal; it did not establish that semaglutide causes NAION. Observational studies of this kind can show association, but confounding factors (underlying cardiovascular risk, pre-existing optic nerve anatomy, obesity-related circulatory changes) cannot be fully ruled out without further controlled evidence.

The MHRA and the European Medicines Agency were both made aware of this signal and committed to monitoring it. The MHRA Yellow Card scheme remains the right route for patients who suspect a link between a medicine and a change in their vision. If you have noticed any change in your eyesight since starting Wegovy, our page on whether Wegovy can affect eyesight covers this question in detail, and reporting through Yellow Card adds to the evidence base that shapes future regulatory decisions, and that matters for everyone on these medicines.

Is this the same as the eye risk mentioned in Wegovy's prescribing information?

Not quite. There are two separate eye-related concerns in semaglutide's clinical record, and conflating them muddles the picture. The first, covered above, is the NAION signal, relatively new, still under active investigation, and most relevant to people without diabetes who are using Wegovy for weight management.

The second is worsening of diabetic retinopathy in people who already have that condition. This is documented in semaglutide's prescribing information and is not a new finding: when blood sugar drops quickly (as it can during the early weeks of semaglutide treatment in people with type 2 diabetes) the retinal blood vessels can be temporarily stressed, and in people with pre-existing retinopathy that stress can accelerate damage. This risk applies most directly to people using semaglutide to manage their diabetes, including those on Ozempic.

For people using Wegovy purely for weight management who do not have diabetes or diabetic retinopathy, the retinopathy concern is less directly relevant, but it is not irrelevant, because some people start Wegovy with undiagnosed prediabetes or borderline blood-sugar levels. A good prescriber will take a full medical history before recommending semaglutide. The NHS patient information for semaglutide is worth reading in full alongside this page, and it includes guidance on what to look out for and when to seek help.

What symptoms should prompt you to contact a doctor or seek urgent help?

The range of side effects reported with semaglutide is wide, and most are gastrointestinal (nausea, loose stools, reflux) rather than visual. But visual symptoms deserve a different level of urgency. Do not wait for your next scheduled review if you experience any of the following.

Sudden blurring or dimming of vision in one eye (even if it seems to ease after a few minutes) is the classic presenting symptom of NAION and needs same-day or emergency assessment. Loss of part of your visual field, particularly in one quadrant, is similarly urgent. Sudden visual disturbance in both eyes at once is more often associated with other causes but still warrants immediate attention. Floaters appearing suddenly in large numbers or accompanied by flashes of light can signal retinal changes and should be assessed promptly too.

Redness, soreness, or gradual blurring that has developed over days and weeks is less likely to represent NAION specifically, though it still deserves an optician or GP review rather than dismissal. If you are also finding your sleep is disturbed, it is worth reading about whether Wegovy can cause sleep problems, as fatigue and poor rest can sometimes make visual symptoms harder to assess clearly. The principle is straightforward: if the change is sudden, act immediately. If it is gradual, do not ignore it.

Our clinical team is available seven days a week for aftercare queries. If you are a patient and you have a concern about your vision, contact us and we will advise on next steps, which may well include directing you straight to an eye casualty department.

Does the current evidence change whether Wegovy is appropriate for you?

Regulators have not withdrawn Wegovy or added a contraindication specifically for people without prior eye disease. The NAION signal prompted enhanced monitoring, not a blanket warning against use. That is the current position as of summer 2026, and it reflects the fact that the absolute risk remains low and the benefits of clinically supervised weight management for eligible adults are substantial and well-documented.

What the evidence does support is transparency at the consultation stage. Someone with a history of NAION, optic nerve abnormality, or significant cardiovascular risk factors may need a more careful conversation with their prescriber before starting semaglutide, and our dedicated page on whether Wegovy causes vision problems sets out the current evidence in full. That is exactly the kind of assessment that a clinical consultation (not an automated sign-up flow) is designed to have. For context on how Wegovy is priced through private services, that information is available separately. The more important point here is that appropriate clinical review is not optional; it is the thing that makes treatment safe.

If you would like to explore whether semaglutide or tirzepatide is suitable for your circumstances, check your eligibility through a free consultation with our GPhC-registered prescribers. Your answers are read by a clinician the same day, the sort of person who will ask about your eye history if it is relevant, and who will flag it if it changes their recommendation.